Clinical trials: In-Stent Coronary Artery Restenosis
Coronary Artery Disease, Stent Restenosis
Intracoronary Optical Coherence Tomography Guidance Vs. Angiography Only Guidance for Treatment of Coronary In-stent Restenosis
Although advances in drug-eluting stents (DES) have substantially reduced the risk of coronary in-stent restenosis (ISR) and the need for target lesion revascularisation (TLR), ISR persists.
- Conditions
- Coronary Artery Disease, Stent Restenosis, STENT
- Trial name
- INSIDE OCT (NCT06779110)
- Testing
- Percutaneous Coronary Intervention
- Where
- 12 sites in Italy
- Volunteers
- 360 people
- Sponsor
- San Luigi Gonzaga Hospital
Coronary Heart Disease, Diabetes
OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA
Rationale IVUS has shown to be efficient for bare metal stent deployment, but has not been specifically studied for Drug Eluting Stents.
- Conditions
- Coronary Heart Disease, Diabetes, Vascular Lesions, Chronic Total Occlusion of Coronary Artery
- Trial name
- OPERA (NCT01861860)
- Testing
- TAXUS™ Element long stent
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Coronary Artery Disease, Coronary Restenosis
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR
AbsorbISR is a randomized, controlled trial, single center, prospective, not blinded to evaluate two strategies of in stent restenosis treatment: Implantation of drug eluting bioresorbable stent scaffold Absorb® vs.
- Trial name
- AbsorbISR (NCT02474485)
- Testing
- BVS Absorb implantation., DEB Sequent Please inflation., Control coronary angiography.
- Where
- Switzerland
- Volunteers
- 53 people
- Sponsor
- SIS Medical AG
Coronary Artery Disease, Coronary Restenosis
Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant…
- Trial name
- NCT00426049
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 484 people
- Sponsor
- German Heart Institute
Coronary Artery Disease, Coronary Stent Restenosis
A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis
The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure.
- Trial name
- NCT00244647
- Testing
- RESTEN-MP
- Volunteers
- 40 people
- Sponsor
- Sarepta Therapeutics, Inc.
In Stent Restenosis, Drug Eluting Stent
A Comparison Between FFR Guided and CAG Guided Treatment Using DEB in ISR of DES
This is a prospective single center, randomized controlled clinical study aimed to compare the clinical and angiographic follow-up results of patients with in-stent restenosis(ISR) after coronary drug eluting stent(DES)…
- Conditions
- In Stent Restenosis, Drug Eluting Stent, Coronary Artery Disease
- Trial name
- NCT04518826
- Testing
- fractional flow reserve
- Volunteers
- 420 people
- Sponsor
- Shanghai Zhongshan Hospital
In-stent Restenosis
Diffuse Type In-Stent Restenosis After Drug-Eluting Stent
To evaluate the best therapeutic option for the treatment of diffuse type post-drug-eluting stent restenosis.
- Trial name
- DES-ISR (NCT00485030)
- Testing
- Cypher, Xience-V
- Where
- 15 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
Comparison of Optical Coherence Tomographic Findings After Balloon Angioplasty With Two Different Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis in Drug-Eluting Stents
Drug-coated balloon technology (DCB) has recently attracted considerable interest as a promising alternative treatment option, particularly in the setting of in-stent restenosis (ISR).
- Trial name
- NCT02528474
- Testing
- balloon angioplasty with Pantera Lux, balloon angioplasty with SeQuent Please
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yonsei University
Coronary Artery Disease
Prevail Global Study
The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.
- Trial name
- NCT06535854
- Testing
- Prevail DCB, Agent DCB
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 1,205 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease, Coronary Restenosis
DEB Versus 2nd Generation DES in Patients With In-Scaffold Restenosis of Bioresorbable Vascular Scaffold
The aim of the study is to compare angiographic outcomes following revascularization using drug-eluting balloon (DEB) versus 2nd generation drug-eluting stent (DES) in treatment of Bioresorbable Vascular Scaffold Restenosis.
- Trial name
- SMART-BRS-ISR (NCT03074305)
- Testing
- PCI for in-bioresorbable scaffold stenosis
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Coronary Disease, Coronary Artery Disease
PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions
PROSPECT is a multi-center prospective registry of Acute Coronary Syndromes (ACS) patients with single or double vessel coronary artery disease.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- NCT00180466
- Where
- 40 sites in United States, Belgium and 10 more
- Volunteers
- 697 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial
The main objective of this study is to assess the safety and effectiveness of the Sirolimus-eluting stent CYPHERTM and/or updated version in reducing angiographic in-stent late loss in de novo native coronary lesions of diabetic…
- Trial name
- DESSERT (NCT00497172)
- Testing
- CYPHER Sirolimus-eluting stent, Bx SONIC bare metal stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Cordis US Corp.
Chronic Total Occlusion of Coronary Artery, Coronary Occlusion
ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.
ABSORB FIRST is a prospective, multi-center registry. The objectives of the study are to: Provide ongoing post-market surveillance for documentation of safety, performance and clinical outcomes of the Absorb BVS (Bioresorbable…
- Conditions
- Chronic Total Occlusion of Coronary Artery, Coronary Occlusion, Coronary Artery Disease, Coronary Artery Restenosis
- Trial name
- NCT01759290
- Testing
- Absorb Bioresorbable Vascular Scaffold
- Where
- Belgium
- Volunteers
- 1,800 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Coronary Occlusion
Non-acute Coronary occlusIon Treated By Everolimus ELuting Stent
Chronic total coronary occlusions (CTO) have an especially high risk of angiographic restenosis, and need for new revascularization procedures.
- Conditions
- Coronary Artery Disease, Coronary Occlusion, Percutaneous Coronary Intervention
- Trial name
- CIBELES (NCT00793221)
- Testing
- Implantation of sirolimus-eluting coronary stent, Implantation of everolimus-eluting coronary stent
- Volunteers
- 207 people
- Sponsor
- Raul Moreno
Stents, Coronary Artery Disease
SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
This study is divided into 5 arms: 1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V®…
- Conditions
- Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis
- Trial name
- NCT00180479
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 65 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- Abbott Medical Devices
Cardiovascular Diseases, Coronary Artery Disease
ABSORB: Postmarketing Surveillance Registry to Monitor the Everolimus-eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease
The registry aims to evaluate the safety, performance and efficacy of the Everolimus-eluting bioresorbable vascular scaffold (BVS) system in patients with de novo native coronary artery lesions in all-day clinical practice.
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease, Myocardial Ischemia, Coronary Disease
- Trial name
- ASSURE (NCT01583608)
- Where
- 6 sites in Germany
- Volunteers
- 183 people
- Sponsor
- Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.
Coronary Artery Disease
Impaired Peripheral Endothelial Function and In-stent Restenosis
The investigators assessed the hypothesis that whether RH-PAT index (RHI) as a marker of endothelial dysfunction could predict occurrence of ISR after percutaneous coronary intervention (PCI).
- Trial name
- NCT02131935
- Where
- Japan
- Volunteers
- 513 people
- Sponsor
- Kumamoto University
Stable Angina, Ischemic Heart Disease Silent
A Randomized Clinical Evaluation of the BioFreedom™ Stent
The purpose of this study is to demonstrate that a BioFreedom™ Drug Coated Stent is non-inferior to a bare metal stent at one year as measured by the composite safety endpoint of cardiovascular death, myocardial infarction and…
- Conditions
- Stable Angina, Ischemic Heart Disease Silent, ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction, In-stent Coronary Artery Restenosis
- Trial name
- Leaders Free (NCT01623180)
- Testing
- Biofreedom™ Drug Coated Stent (DCS), Gazelle™ Bare Metal Coronary Stent (BMS)
- Where
- Switzerland
- Volunteers
- 2,456 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease, In-stent Restenosis
To Study and Explore the Predictive Effect of Insulin Resistance-related Indicators on In-stent Restenosis After Coronary Stent Implantation
Based on previous studies on insulin resistance and cardiovascular diseases, we believe that the insulin resistance metabolic score also has certain predictive value for the prognosis of in-stent restenosis after coronary stent…
- Trial name
- NCT07614763
- Testing
- Observational studies do not design intervention measures
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Qilu Hospital of Shandong University
Coronary Artery Stenosis, Coronary Arteriosclerosis
XIENCE V: SPIRIT WOMEN Sub-study
The purpose of this Clinical Evaluation is the continued assessment of the XIENCE Everolimus Eluting Coronary Stent System (XIENCE V® and XIENCE PRIME™ EECSS) with the primary focus on clinical outcomes in the treatment of female…
- Conditions
- Coronary Artery Stenosis, Coronary Arteriosclerosis, Coronary Artery Disease, Coronary Artery Restenosis
- Trial name
- NCT01182428
- Testing
- XIENCE V®/ XIENCE PRIME™, CYPHER SELECT
- Where
- 25 sites in Argentina, Austria and 13 more
- Volunteers
- 455 people
- Sponsor
- Abbott Medical Devices